ArticleExploration of targeted anti-tumor therapy2021

Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.

Edoardo Lenci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.